心力衰竭中的矿物质皮质类受体对手:系统性审查和元分析
Yue Zhang1, Yin-Chao Bao1, Li-Xia Wang2
1Tongji University School of Medicine, Shanghai, China.
Frontiers in cardiovascular medicine
|September 17, 2025
概括
矿物质皮质类受体抗剂 (MRAs) 显著降低了心血管复合结局和心力衰竭的住院治疗,减少了喷射分数 (HFrEF). 虽然在轻微减少或保留射出分数 (HFmrEF/HFpEF) 的心力衰竭中益处很小,但由于高血症风险增加,需要仔细监测水平.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 矿物质皮质类受体 (MRA) 的过度激活导致心肌纤维化,血管炎症和心力衰竭 (HF) 中的保留在左心室喷射小部分 (LVEF) 的整个频谱中.
- 类固醇MRA在HFrEF中表现出有效性,但对HFmrEF和HFpEF的证据有限.
- 由于缺乏类固醇和非类固醇MRA之间的对比比较,因此需要进一步评估.
研究的目的:
- 评估MRA在HF患者的有效性和安全性,包括LVEF的全部范围.
- 综合随机临床试验 (RCT) 关于MRA在HF使用的证据.
- 为了比较HFrEF与HFmrEF/HFpEF群体中的MRA效应.
主要方法:
- 从1987年1月1日到2024年9月10日,在PubMed,科学网,万芳和柯克兰图书馆进行了系统的文献搜索.
- 包括在内的RCT评估了HFpEF,HFmrEF或HF患者的MRA (费内伦,螺旋乳,埃普莱伦).
- 对初级复合心血管 (CV) 结果和二级终点进行了元分析,使用危险比率 (HR),置信区间 (CI) 和相对风险 (RR).
主要成果:
- 在HFrEF患者中,MRAs降低了23%的复合CV结局 (RR:0.77) 和23%的HF住院 (HR:0.77).
- 在HFmrEF/HFpEF患者中,MRAs显示复合心血管事件 (HR:0.85) 减少了17%,HF住院病例 (HR:0.80) 减少了20%.
- 在MRA组中,高血症的发生率显著高 (RR:2.19),而整体严重不良事件与安慰剂相似.
结论:
- 对于HFrEF患者来说,MRA提供了巨大的好处,应该被视为标准治疗.
- 在HFmrEF和HFpEF方面,MRA可能会提供适度的好处,但需要对高卡利米亚进行仔细监测.
- 当在HF患者使用MRA时,密切监测水平至关重要,特别是那些患有HFmrEF/HFpEF的人.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:22Heart Failure Drugs: Diuretics
809
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
809
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:22Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K